Showing results (921-930 of 1,024) with videos related to

Sort By:
Pageof 103
Psycho-Oncology|June 22, 2019
Sensitivity to change of the EORTC quality of life module measuring cancer-related fatigue (EORTC QlQ-Fa12): Results from the international psychometric validationJoachim Weis, Markus A Wirtz, Krzysztof A Tomaszewski, et al.
Advances in Marine Biology|June 2, 2014
Transitions during cephalopod life history: the role of habitat, environment, functional morphology and behaviourJean-Paul Robin, Michael Roberts, Lou Zeidberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host DiseaseSumithira Vasu, Susan Geyer, Anissa Bingman, et al.
JCI Insight|April 24, 2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathyJithendra Kini Bailur, Samuel S McCachren, Deon B Doxie, et al.
Blood|December 6, 2017
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemiaChristine Chen, David Siegel, Martin Gutierrez, et al.
Microscopy and Microanalysis : the Official Journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada|January 22, 2014
A microfluidic-enabled mechanical microcompressor for the immobilization of live single- and multi-cellular specimensYingjun Yan, Liwei Jiang, Karl J Aufderheide, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 27, 2016
International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15Marianne J Hjermstad, Mia Bergenmar, Kristin Bjordal, et al.
British Journal of Haematology|June 26, 2018
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myelomaPaul G Richardson, Craig C Hofmeister, Cara A Rosenbaum, et al.
Oncotarget|October 3, 2015
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomideAlessandro Canella, Hector Cordero Nieves, Douglas W Sborov, et al.
Blood|May 13, 2010
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibodyDon M Benson, Courtney E Bakan, Anjali Mishra, et al.
Pageof 103